Our capabilities

We offer expertise in clinical and translational research and genomic testing. Our extensive portfolio spans first-in-class, first-in-child, precision medicine and complex innovative design trials.

Contact us through our partnering form

Clinical research

We have a proven capability in delivering precision medicine trials in novel therapies across treatment modalities and technologies.

Dark blue icon indicating a syringe.

Immunotherapy​

  • first-in-human and first-in-class novel agent trials with expertise in:

    • CAR-T (including solid and paediatric tumours)​

    • autologous TCR-engineered T cells​

    • unconventional T cells​

    • cancer vaccines​

    • oncolytic virus​

    • tumour-infiltrating lymphocytes​

  • manufacturing facilities and platforms​

  • specialist advanced therapy medicinal products pharmacists and staff​

Dark blue icon indicating a test tube.

Haematology

  • diverse early-phase haematology expertise and access to patient groups​ in

    • leukaemia (acute and chronic lymphoblastic, acute and chronic myeloid, chronic myelomonocytic)

    • lymphoma​

    • myeloma​

    • myelodysplastic syndromes

    • myeloproliferative neoplasms​

  • expertise in stem cell transplantation and cellular therapies, serological biomarkers, T cell and bone microenvironment fitness

Dark blue icon indicating a beaker.

Pharmacology

  • pharmacokinetics/pharmacodynamics analyses​

  • drug-drug interaction studies​

  • food-effect drug studies​

  • therapeutic drug monitoring programme for neonates and infants​

Dark blue icon indicating a magnifying glass.

Radiotherapy and imaging​

  • design and delivery of complex trials including surgery, radiotherapy-drug combination and novel imaging trials​

Translational research

Our network supports pre-clinical and translational research questions across a range of cancer types.

  • pre-clinical models​

  • ex-vivo/patient derived explant models​

  • patient sample collections/biobanks​

  • GCLP accredited facilities for sample tracking, biomarker assay discovery and validation​

  • ctDNA and cfDNA profiling and subtyping​

  • immune profiling​

  • digital pathology

Genomic testing

We have access to comprehensive genomic profiling via the Genomic MedicineService and various research platform studies.

TARGET National

Our liquid-based molecular profiling programme aims to establish a national framework to offer molecular profiling of circulating tumour DNA to patients with advanced solid cancers. Currently includes 324 gene panel on ctDNA.

Genomic Medicine Service​

Whole-genome and targeted panel sequencing for children, teenagers and young adults, brain tumour patients and in haematology​. Aimed at solid tumours with sequencing expanding to include targets relevant for clinical trial eligibility​.

You might also be interested in

How we work

Learn more about how we support our network and our partners to successfully collaborate and deliver early-phase clinical trials.

Industry and partners

We are a centralised platform for commercial partners to launch trials quickly with access to expert teams, sites and processes.

Latest news

Explore the latest articles, updates, interviews and news from our network.